dynamic-pdf

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Log Out

Therapy Areas

Products

Order Vaccines

Order Samples

Order

Materials

Request Samples

Hospital Products

Vaccines

Patient Assistance

Pfizer Oncology Together

Pfizer RxPathways

Pfizer Dermatology Patient Access

Explore Content

Contact

Home

About

Dosing

Efficacy

Adult: Relapsed or
Refractory Patients
With Ph- or Ph+ ALL

Pediatric: Relapsed or
Refractory CD22-
Positive Patients With
B-cell Precursor ALL

Safety

Adult Safety

Pediatric Safety

Savings & Support

Events

Materials

Videos

Personalized patient support

Ordering BESPONSA

NCCN Guidelines® Recommendations

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-INO-USA-0658

You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION

BESPONSA® (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).